Leerink Partnrs Has Optimistic Outlook of CRSP Q3 Earnings

Key Points

• Leerink Partners has adjusted its Q3 2025 earnings estimate for CRISPR Therapeutics to ($1.58) per share, slightly improving from the previous estimate of ($1.62) per share.
• CRISPR Therapeutics' most recent quarterly earnings reported a loss of ($1.29) per share, exceeding expectations of ($1.47) and showcasing a year-over-year revenue increase of 72.5% despite a considerable net loss.
• Analysts have mixed ratings for CRISPR Therapeutics, with ten analysts rating it "Buy," seven as "Hold," and two as "Sell," resulting in an average target price of $71.71.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Leerink Partnrs upped their Q3 2025 earnings estimates for CRISPR Therapeutics in a report released on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($1.58) per share for the quarter, up from their previous forecast of ($1.62). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics' Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($5.38) EPS and FY2026 earnings at ($5.38) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The company had revenue of $0.89 million for the quarter, compared to analysts' expectations of $6.44 million. During the same quarter in the previous year, the company earned ($1.49) earnings per share. CRISPR Therapeutics's quarterly revenue was up 72.5% on a year-over-year basis.

Other equities analysts have also recently issued research reports about the stock. Royal Bank Of Canada boosted their price target on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a "sector perform" rating in a research report on Tuesday, August 5th. JMP Securities reissued a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, June 27th. JPMorgan Chase & Co. initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday, September 18th. They set an "overweight" rating and a $70.00 price target for the company. Zacks Research raised shares of CRISPR Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 26th. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, September 23rd. Ten analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $71.71.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $68.43 on Friday. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $78.48. The company's 50-day moving average is $60.15 and its 200 day moving average is $49.75. The stock has a market capitalization of $6.22 billion, a P/E ratio of -12.60 and a beta of 1.84.

Insider Activity

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the transaction, the general counsel directly owned 83,402 shares of the company's stock, valued at approximately $5,554,573.20. The trade was a 1.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samarth Kulkarni sold 4,242 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $282,517.20. Following the completion of the transaction, the chief executive officer directly owned 205,096 shares of the company's stock, valued at $13,659,393.60. This trade represents a 2.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. IFP Advisors Inc raised its stake in shares of CRISPR Therapeutics by 24.6% in the second quarter. IFP Advisors Inc now owns 916 shares of the company's stock valued at $45,000 after acquiring an additional 181 shares during the period. Cerity Partners LLC raised its stake in shares of CRISPR Therapeutics by 3.0% in the second quarter. Cerity Partners LLC now owns 6,541 shares of the company's stock valued at $318,000 after acquiring an additional 190 shares during the period. Peapack Gladstone Financial Corp raised its stake in shares of CRISPR Therapeutics by 3.0% in the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company's stock valued at $339,000 after acquiring an additional 200 shares during the period. Ipswich Investment Management Co. Inc. raised its stake in shares of CRISPR Therapeutics by 0.9% in the third quarter. Ipswich Investment Management Co. Inc. now owns 25,198 shares of the company's stock valued at $1,633,000 after acquiring an additional 230 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in shares of CRISPR Therapeutics by 1.1% in the second quarter. Teacher Retirement System of Texas now owns 22,066 shares of the company's stock valued at $1,073,000 after acquiring an additional 243 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.